$5.69 Billion in Sales Expected for Thermo Fisher Scientific Inc. (TMO) This Quarter
Analysts forecast that Thermo Fisher Scientific Inc. (NYSE:TMO) will post $5.69 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Thermo Fisher Scientific’s earnings, with the highest sales estimate coming in at $5.73 billion and the lowest estimate coming in at $5.64 billion. Thermo Fisher Scientific posted sales of $4.95 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 14.9%. The company is scheduled to announce its next earnings results before the market opens on Wednesday, January 31st.
According to Zacks, analysts expect that Thermo Fisher Scientific will report full-year sales of $5.69 billion for the current financial year, with estimates ranging from $20.51 billion to $20.75 billion. For the next year, analysts expect that the firm will post sales of $22.95 billion per share, with estimates ranging from $22.78 billion to $23.38 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Thermo Fisher Scientific.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.03 earnings per share.
Shares of Thermo Fisher Scientific (TMO) traded up $3.47 on Thursday, hitting $211.48. 1,461,900 shares of the company traded hands, compared to its average volume of 1,600,827. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85. The stock has a market capitalization of $84,710.00, a P/E ratio of 35.90, a price-to-earnings-growth ratio of 1.69 and a beta of 1.06. Thermo Fisher Scientific has a fifty-two week low of $140.00 and a fifty-two week high of $211.81.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, January 15th. Stockholders of record on Friday, December 15th were given a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.28%. The ex-dividend date was Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is currently 10.19%.
In other news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $191.74, for a total value of $9,587,000.00. Following the completion of the sale, the chief executive officer now owns 302,577 shares of the company’s stock, valued at $58,016,113.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.49% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in TMO. Bank of Nova Scotia Trust Co. acquired a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $106,000. Ropes Wealth Advisors LLC grew its holdings in Thermo Fisher Scientific by 15.8% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 97 shares in the last quarter. Atlantic Trust LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $138,000. Acrospire Investment Management LLC grew its holdings in Thermo Fisher Scientific by 66.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,000 shares of the medical research company’s stock valued at $174,000 after purchasing an additional 400 shares in the last quarter. Finally, Glassman Wealth Services grew its holdings in Thermo Fisher Scientific by 23.1% during the 2nd quarter. Glassman Wealth Services now owns 1,039 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 195 shares in the last quarter. 86.25% of the stock is owned by institutional investors.
WARNING: “$5.69 Billion in Sales Expected for Thermo Fisher Scientific Inc. (TMO) This Quarter” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/18/5-69-billion-in-sales-expected-for-thermo-fisher-scientific-inc-tmo-this-quarter.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.